University of Arizona startup that is commercializing error-correction technology for data storage and communications, has reported that it has raised approximately $700,000 in a round of angel investment funding.
Between 2013 and July 2016, TLA provided almost $2.2 million in Asset Development funding to prepare 82 early-stage technologies for licensing. So far in FY 2017, we have provided funds for seven projects and expect to award an additional four or five by the end of June.
The University of Arizona has licensed a new tunable laser technology invented in the College of Optical Sciences to startup TPhotonics, Inc. The technology allows for devices that can produce a beam and tweak its wavelength on-the-fly.
In recognition of his prolific work as an impactful innovator and educator, optical sciences professor Nasser Peyghambarian, Ph.D. has been elected as a 2017 Fellow of the National Academy of Inventors. Read more. >
What do you need for a successful commercialization ecosystem? First, you need great inventions, such as those stemming from UA research. But just as important, you need great, experienced, committed people – lots of them – to provide the right expertise at the right time.
From left to right: Doug Hockstad, TLA sr. director of technology transfer; David Allen, Ph.D., vice president of TLA; Kwansun Ahn, M.B.A., Anivive CEO; Dylan Balsz, Anivive co-founder; Codey Arbuckle, Ph.D., Anivive director of engineering; Warren Rickard, Anivive co-founder; and Paul Eynott, Ph.D., TLA sr. licensing manager. Photo credit: Taylor Hudson/Tech Launch Arizona
The University of Arizona has exclusively licensed the rights to a novel kinase inhibitor, which is efficacious for the treatment of a variety of solid tumors in canines, to Anivive Lifesciences.
At the Get Started Tucson business pitch competition, judges selected just eight teams out of a pool of 69 applicant companies to pitch at the Tucson version of ABC’s Shark Tank. Of those, two were companies working to commercialize technologies invented at the UA.
UA researchers, in collaboration with the University of California San Francisco, have developed a new treatment for acute myeloid leukemia. The team has formed a startup – Promutech Pharmaceuticals, Inc. – to further develop and commercialize the treatment.
The UA, through TLA, has partnered with TechCode, a global network of startup incubators and entrepreneurial ecosystems. TechCode will provide networking resources to increase the reach and effectiveness of TLA’s technology innovations and startups.
UPDATE: This year, we initially reported our results on August 30. Regrettably, on September 30, we discovered that two FY2016 agreements were misclassified in our system. We've since updated our process and documents.